Manager TitleAgeSince
Chief Operating Officer - 2022-11-13
Director TitleAgeSince
Director/Board Member 61 2005-08-15
Chairman 67 2014-09-18
Director/Board Member 55 2008-06-04
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.38%+1.33%-14.32%-11.76% 23.75B
+1.17%+5.83%+16.39%+468.18% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.79%+4.91%+29.26%+195.60% 13.96B
Average -2.02%+5.83%+56.30%+150.72% 27.06B
Weighted average by Cap. -0.40%+3.31%+57.92%+139.30%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14